Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10370 Combinations in KRAS G12C Advanced Solid Tumors
NCT06594874Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hs-10370 in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Number of Participants with Adverse Event(s) (AEs) at 2 years. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
hs-10370
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06594874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06594874.